ABCL — AbCellera Biologics Share News
0.000.00%
- $3.75bn
- $2.99bn
- $75.13m
Brief: AbCellera Biologics Files For Mixed Shelf, Size Not Disclosed - SEC Filing
Abcellera Biologics Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: AbCellera Q3 Revenue USD 6.5 Million Vs. IBES Estimate USD 7.95 Million
Abcellera Biologics Inc reports results for the quarter ended in June - Earnings Summary
Brief: AbCellera Q2 Revenue USD 7.3 Million Vs. IBES Estimate USD 10.2 Million
Abcellera Biologics Inc reports results for the quarter ended in March - Earnings Summary
Brief: AbCellera Q1 Revenue USD 10 Million Vs. IBES Estimate USD 10.8 Million
Abcellera Biologics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Abcellera, Viking Global Investors And Arrowmark Partners Collaborate To Launch New Biotech Companies
Brief: Abcellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
Brief: AbCellera Announces Resignation Of Board Member
Abcellera Biologics Inc reports results for the quarter ended in December - Earnings Summary
Brief: AbCellera Q4 Revenue USD 9.2 Million Vs. IBES Estimate USD 8.88 Million
Abcellera Biologics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: AbCellera Biologics Announces Reorganization And Associated Reduction In Its Workforce
Abcellera Biologics Inc reports results for the quarter ended in September - Earnings Summary
Abcellera Biologics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: AbCellera Biologics Took Ownership Of Antibody Drug Candidate, Discovered By Co As Part Of a Collaboration With Eqrx
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx